Drugs / Flu Seasonal
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06680375 | Nov 2024 → Jun 2025 | COVID-19 | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-01 | GlaxoSmithKline | Results GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data gsk.com ↗
GSK’s vaccine candidate showed higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines in younger and older adults respectively, and was generally well tolerated. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-01 | GlaxoSmithKline | GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data gsk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu Seasonal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680375 ↗ |
| Modality | Vaccine | “A licensed Flu Seasonal vaccine will be administered.” NCT06680375 ↗ |